Thomas Seck Full Interview

In this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about new data on the effects of Empagliflozin and how it compares to the standard of care in terms of cardiovascular death, overall mortality independent of changes in blood pressure, in HbA1C and in blood lipids.

Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.

To view the transcript of this interview, click here.

Return to the main page.